J.W. Cole Advisors Inc. Buys 109 Shares of Elevance Health, Inc. (NYSE:ELV)

J.W. Cole Advisors Inc. increased its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 12.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 994 shares of the company’s stock after acquiring an additional 109 shares during the period. J.W. Cole Advisors Inc.’s holdings in Elevance Health were worth $469,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of ELV. International Assets Investment Management LLC raised its holdings in Elevance Health by 45,888.1% during the fourth quarter. International Assets Investment Management LLC now owns 255,694 shares of the company’s stock worth $1,205,750,000 after acquiring an additional 255,138 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Elevance Health by 212.7% during the third quarter. Assenagon Asset Management S.A. now owns 366,833 shares of the company’s stock worth $159,726,000 after acquiring an additional 249,533 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec raised its stake in Elevance Health by 57.7% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 640,905 shares of the company’s stock valued at $279,063,000 after buying an additional 234,439 shares during the period. Schroder Investment Management Group raised its stake in Elevance Health by 18.2% in the third quarter. Schroder Investment Management Group now owns 1,330,883 shares of the company’s stock valued at $579,493,000 after buying an additional 204,715 shares during the period. Finally, Qube Research & Technologies Ltd raised its stake in Elevance Health by 59.3% in the third quarter. Qube Research & Technologies Ltd now owns 491,504 shares of the company’s stock valued at $214,011,000 after buying an additional 182,889 shares during the period. Institutional investors own 89.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ELV shares. Royal Bank of Canada upped their price objective on Elevance Health from $574.00 to $575.00 and gave the company an “outperform” rating in a research note on Friday, April 19th. Cantor Fitzgerald restated an “overweight” rating and issued a $580.00 price objective on shares of Elevance Health in a research note on Wednesday, April 10th. Barclays upped their price objective on Elevance Health from $584.00 to $621.00 and gave the company an “overweight” rating in a research note on Friday, April 19th. StockNews.com lowered Elevance Health from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 25th. Finally, Truist Financial restated a “buy” rating and issued a $600.00 price objective (up previously from $580.00) on shares of Elevance Health in a research note on Friday, April 19th. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $587.64.

Insider Buying and Selling

In other Elevance Health news, Director Ramiro G. Peru sold 753 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $500.00, for a total value of $376,500.00. Following the sale, the director now owns 9,109 shares of the company’s stock, valued at approximately $4,554,500. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.29% of the stock is currently owned by company insiders.

Elevance Health Trading Up 0.1 %

Shares of NYSE:ELV opened at $532.92 on Wednesday. The company has a market capitalization of $123.86 billion, a P/E ratio of 20.14, a P/E/G ratio of 1.16 and a beta of 0.78. Elevance Health, Inc. has a 1 year low of $412.00 and a 1 year high of $539.11. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.37 and a quick ratio of 1.37. The business’s 50 day simple moving average is $510.23 and its 200 day simple moving average is $485.10.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Thursday, April 18th. The company reported $10.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.54 by $0.10. The business had revenue of $42.27 billion for the quarter, compared to the consensus estimate of $42.49 billion. Elevance Health had a return on equity of 20.62% and a net margin of 3.64%. The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $9.46 earnings per share. On average, research analysts anticipate that Elevance Health, Inc. will post 37.24 EPS for the current fiscal year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 25th. Investors of record on Monday, June 10th will be given a dividend of $1.63 per share. This represents a $6.52 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date of this dividend is Monday, June 10th. Elevance Health’s dividend payout ratio is currently 24.64%.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.